Cargando…

Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report

BACKGROUND: Pneumatosis intestinalis (PI) is defined as the presence of gas in the bowel wall and is a relatively rare finding. PI has been associated with various pathological conditions and medications. Although several chemotherapeutic agents and molecular targeted therapy agents are reported to...

Descripción completa

Detalles Bibliográficos
Autores principales: Maeda, Ai, Nakata, Masao, Shimizu, Katsuhiko, Yukawa, Takuro, Saisho, Shinsuke, Okita, Riki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974742/
https://www.ncbi.nlm.nih.gov/pubmed/27495256
http://dx.doi.org/10.1186/s12957-016-0926-1
_version_ 1782446600938848256
author Maeda, Ai
Nakata, Masao
Shimizu, Katsuhiko
Yukawa, Takuro
Saisho, Shinsuke
Okita, Riki
author_facet Maeda, Ai
Nakata, Masao
Shimizu, Katsuhiko
Yukawa, Takuro
Saisho, Shinsuke
Okita, Riki
author_sort Maeda, Ai
collection PubMed
description BACKGROUND: Pneumatosis intestinalis (PI) is defined as the presence of gas in the bowel wall and is a relatively rare finding. PI has been associated with various pathological conditions and medications. Although several chemotherapeutic agents and molecular targeted therapy agents are reported to be associated with PI, there have been few reports describing the association between the anti-epidermal growth factor receptor agent gefitinib, a tyrosine kinase inhibitor (TKI), and PI. The present report describes a case of PI secondary to gefitinib therapy. CASE PRESENTATION: An 80-year-old woman who had been diagnosed with recurrent lung adenocarcinoma presented with remarkable appetite loss, abdominal distension, and constipation after starting gefitinib therapy. A computed tomography (CT) scan of the abdomen revealed PI extending from the small intestine to the rectum. The patient was managed conservatively, and gefitinib therapy was discontinued. Subsequently, the symptoms improved and a follow-up abdominal X-ray showed a reduction in intramural air. After gefitinib was restarted, PI occurred three more times. CONCLUSIONS: Although PI is extremely rare, physicians should be aware of the risk of PI in patients undergoing gefitinib therapy.
format Online
Article
Text
id pubmed-4974742
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49747422016-08-06 Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report Maeda, Ai Nakata, Masao Shimizu, Katsuhiko Yukawa, Takuro Saisho, Shinsuke Okita, Riki World J Surg Oncol Case Report BACKGROUND: Pneumatosis intestinalis (PI) is defined as the presence of gas in the bowel wall and is a relatively rare finding. PI has been associated with various pathological conditions and medications. Although several chemotherapeutic agents and molecular targeted therapy agents are reported to be associated with PI, there have been few reports describing the association between the anti-epidermal growth factor receptor agent gefitinib, a tyrosine kinase inhibitor (TKI), and PI. The present report describes a case of PI secondary to gefitinib therapy. CASE PRESENTATION: An 80-year-old woman who had been diagnosed with recurrent lung adenocarcinoma presented with remarkable appetite loss, abdominal distension, and constipation after starting gefitinib therapy. A computed tomography (CT) scan of the abdomen revealed PI extending from the small intestine to the rectum. The patient was managed conservatively, and gefitinib therapy was discontinued. Subsequently, the symptoms improved and a follow-up abdominal X-ray showed a reduction in intramural air. After gefitinib was restarted, PI occurred three more times. CONCLUSIONS: Although PI is extremely rare, physicians should be aware of the risk of PI in patients undergoing gefitinib therapy. BioMed Central 2016-06-29 /pmc/articles/PMC4974742/ /pubmed/27495256 http://dx.doi.org/10.1186/s12957-016-0926-1 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Maeda, Ai
Nakata, Masao
Shimizu, Katsuhiko
Yukawa, Takuro
Saisho, Shinsuke
Okita, Riki
Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report
title Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report
title_full Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report
title_fullStr Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report
title_full_unstemmed Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report
title_short Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report
title_sort pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974742/
https://www.ncbi.nlm.nih.gov/pubmed/27495256
http://dx.doi.org/10.1186/s12957-016-0926-1
work_keys_str_mv AT maedaai pneumatosisintestinalisaftergefitinibtherapyforpulmonaryadenocarcinomaacasereport
AT nakatamasao pneumatosisintestinalisaftergefitinibtherapyforpulmonaryadenocarcinomaacasereport
AT shimizukatsuhiko pneumatosisintestinalisaftergefitinibtherapyforpulmonaryadenocarcinomaacasereport
AT yukawatakuro pneumatosisintestinalisaftergefitinibtherapyforpulmonaryadenocarcinomaacasereport
AT saishoshinsuke pneumatosisintestinalisaftergefitinibtherapyforpulmonaryadenocarcinomaacasereport
AT okitariki pneumatosisintestinalisaftergefitinibtherapyforpulmonaryadenocarcinomaacasereport